Onl therapeutics announces randomization of first patient in global phase 2 galaxy trial of xelafaslatide (onl1204) in patients with geographic atrophy (ga) associated with dry amd

Approvals received from world health organization and united states adopted names council establishing “xelafaslatide” as nonproprietary name for onl1204 ophthalmic solution approvals received from world health organization and united states adopted names council establishing “xelafaslatide” as nonproprietary name for onl1204 ophthalmic solution
AMD Ratings Summary
AMD Quant Ranking